Asthma is chronic inflammation of the airways characterized by airway hyper-responsiveness,wheezing,cough,and dyspnea.Asthma affects>350 million people worldwide.The Th2 immune response is a major contributor to th...Asthma is chronic inflammation of the airways characterized by airway hyper-responsiveness,wheezing,cough,and dyspnea.Asthma affects>350 million people worldwide.The Th2 immune response is a major contributor to the pathophysiology of asthma.Targeted therapy modulating cell signaling pathways can be a powerful strategy to design new drugs to treat asthma.The potential molecular pathways that can be targeted include IL-4-IL-13-JAK-STAT-MAP kinases,adiponectin-iNOS-NF-κB,PGD2-CRTH2,IFNs-RIG,Wnt/β-catenin-FAM13A,FOXC1-miR-PI3K/AKT,JNK-Gal-7,Nrf2-ROS,Foxp3-RORγt,CysLTR,AMP,Fas-FasL,PTHrP/PPARγ,PAI-1,FcɛRI-LAT-SLP-76,Tim-3-Gal-9,TLRs-MyD88,PAR2,and Keap1/Nrf2/ARE.Therapeutic drugs can be designed to target one or more of these pathways to treat asthma.展开更多
文摘Asthma is chronic inflammation of the airways characterized by airway hyper-responsiveness,wheezing,cough,and dyspnea.Asthma affects>350 million people worldwide.The Th2 immune response is a major contributor to the pathophysiology of asthma.Targeted therapy modulating cell signaling pathways can be a powerful strategy to design new drugs to treat asthma.The potential molecular pathways that can be targeted include IL-4-IL-13-JAK-STAT-MAP kinases,adiponectin-iNOS-NF-κB,PGD2-CRTH2,IFNs-RIG,Wnt/β-catenin-FAM13A,FOXC1-miR-PI3K/AKT,JNK-Gal-7,Nrf2-ROS,Foxp3-RORγt,CysLTR,AMP,Fas-FasL,PTHrP/PPARγ,PAI-1,FcɛRI-LAT-SLP-76,Tim-3-Gal-9,TLRs-MyD88,PAR2,and Keap1/Nrf2/ARE.Therapeutic drugs can be designed to target one or more of these pathways to treat asthma.
